MARK3

microtubule affinity regulating kinase 3, the group of Microtubule affinity regulating kinases

Basic information

Region (hg38): 14:103385377-103503831

Links

ENSG00000075413NCBI:4140OMIM:602678HGNC:6897Uniprot:P27448AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • visual impairment and progressive phthisis bulbi (Limited), mode of inheritance: AR
  • visual impairment and progressive phthisis bulbi (Limited), mode of inheritance: AR
  • visual impairment and progressive phthisis bulbi (Limited), mode of inheritance: Unknown

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Visual impairment and progressive phthisis bulbiARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingOphthalmologic29771303

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MARK3 gene.

  • not_specified (70 variants)
  • MARK3-related_disorder (11 variants)
  • not_provided (1 variants)
  • Visual_impairment_and_progressive_phthisis_bulbi (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MARK3 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001128918.3. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
3
clinvar
3
clinvar
6
missense
1
clinvar
70
clinvar
2
clinvar
1
clinvar
74
nonsense
0
start loss
0
frameshift
0
splice donor/acceptor (+/-2bp)
0
Total 1 0 70 5 4

Highest pathogenic variant AF is 0.000031597534

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MARK3protein_codingprotein_codingENST00000429436 18118440
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.000001431.001247650321247970.000128
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.513444320.7960.00002494941
Missense in Polyphen133216.550.614192411
Synonymous-0.3861641581.040.000009381441
Loss of Function3.421740.50.4200.00000236481

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004340.000433
Ashkenazi Jewish0.00009930.0000993
East Asian0.0001110.000111
Finnish0.000.00
European (Non-Finnish)0.0001330.000132
Middle Eastern0.0001110.000111
South Asian0.0001400.000131
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule- associated protein MAPT/TAU (PubMed:23666762). Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus (PubMed:16980613). Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1 (PubMed:28087714). {ECO:0000269|PubMed:16980613, ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:28087714}.;
Disease
DISEASE: Note=Defects in MARK3 may be involved in an autosomal recessive ocular disease characterized by visual impairment manifested at birth, and progressive eye degeneration. {ECO:0000269|PubMed:29771303}.;
Pathway
MAP2K and MAPK activation;RAF activation;Disease;Signal Transduction;Negative regulation of MAPK pathway;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;Signaling by RAS mutants;Signaling by high-kinase activity BRAF mutants;Signaling by moderate kinase activity BRAF mutants;Paradoxical activation of RAF signaling by kinase inactive BRAF;Signaling by BRAF and RAF fusions;Oncogenic MAPK signaling;Diseases of signal transduction (Consensus)

Recessive Scores

pRec
0.163

Intolerance Scores

loftool
0.894
rvis_EVS
-0.69
rvis_percentile_EVS
15.27

Haploinsufficiency Scores

pHI
0.398
hipred
Y
hipred_score
0.648
ghis
0.571

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.974

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Mark3
Phenotype
homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; liver/biliary system phenotype;

Gene ontology

Biological process
MAPK cascade;microtubule cytoskeleton organization;protein phosphorylation;peptidyl-serine phosphorylation;establishment of cell polarity;positive regulation of protein binding;negative regulation of hippo signaling;intracellular signal transduction;peptidyl-serine autophosphorylation
Cellular component
cytoplasm;cytosol;plasma membrane;dendrite;extracellular exosome
Molecular function
protein serine/threonine kinase activity;protein binding;ATP binding;tau protein binding;tau-protein kinase activity